Get the Stockscreener App
1.62
33.88%
0.41
After Hours:
1.55
-0.07
-4.32%
Inozyme Pharma Inc stock is traded at $1.62, with a volume of 8.02M.
It is up +33.88% in the last 24 hours and up +74.87% over the past month.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
See More
Previous Close:
$1.21
Open:
$1.21
24h Volume:
8.02M
Relative Volume:
12.60
Market Cap:
$63.23M
Revenue:
-
Net Income/Loss:
$-71.17M
P/E Ratio:
-1.1655
EPS:
-1.39
Net Cash Flow:
$-70.97M
1W Performance:
+64.60%
1M Performance:
+74.87%
6M Performance:
-62.84%
1Y Performance:
-65.16%
1-Day Range:
$1.18
$1.85
1-Week Range:
$0.9326
$1.85
52-Week Range:
$0.721
$6.24
Inozyme Pharma Inc Stock (INZY) Company Profile
Name
Inozyme Pharma Inc
Sector
Industry
Phone
857-330-4340
Address
321 SUMMER STREET, BOSTON
Compare INZY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
1.62 | 63.23M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Raymond James | Outperform |
| Sep-12-24 | Initiated | Stifel | Buy |
| Aug-13-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| Mar-23-23 | Upgrade | Jefferies | Hold → Buy |
| May-26-22 | Initiated | Jefferies | Hold |
| Feb-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-29-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Inozyme Pharma Inc Stock (INZY) Latest News
JPMorgan Chase & Co. Acquires 99,944 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc’s Shares Reel: -19.01% Quarterly Revenue Decline Amid 73.87M Market Cap - investchronicle.com
INZY Stock Sees Surge of Approximately 17.28% in Last Five Days - knoxdaily.com
Are Inozyme Pharma Inc’shares a good deal? - uspostnews.com
Eventide Asset Management, LLC Reduces Stake in Inozyme Pharma I - GuruFocus
Renaissance Technologies LLC Buys 256,599 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc [NASDAQ: INZY] Sees Decrease in Stock Value - knoxdaily.com
Financial Snapshot: Analyzing Inozyme Pharma Inc (INZY)’s Key Ratio Metrics - DWinneX
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Is Now A Good Time To Invest In Inozyme Pharma Inc (NASDAQ: INZY)? - Stocksregister
Wellington Management Group LLP Lowers Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Raymond James Financial Inc. Invests $205,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
H.C. Wainwright maintains Buy on Inozyme stock with $16 target By Investing.com - Investing.com India
H.C. Wainwright maintains Buy on Inozyme stock with $16 target - Investing.com
Inozyme Pharma (INZY) Publishes Comprehensive Study on ENPP1 Def - GuruFocus
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Rea - GuruFocus
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency - The National Law Review
INZY stock touches 52-week low at $0.77 amid market challenges - Investing.com UK
Rare Disease Innovator Inozyme Pharma Reveals Latest Progress at Elite Healthcare Conference - Stock Titan
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Inozyme Pharma Inc (NASDAQ: INZY) Has Decreased By -82.88 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline By Investing.com - Investing.com South Africa
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline - Investing.com Australia
FY2027 EPS Estimates for Inozyme Pharma Raised by Analyst - Defense World
Raymond James Issues Pessimistic Forecast for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush - Defense World
Q1 EPS Estimates for Inozyme Pharma Reduced by HC Wainwright - Defense World
Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - insights.citeline.com
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $15.00 at Needham & Company LLC - Defense World
Inozyme Pharma’s (INZY) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Piper Sandler cuts Inozyme Pharma stock target to $23 By Investing.com - Investing.com Australia
Inozyme Pharma stock hits 52-week low at $1.03 amid sharp decline - Investing.com
Piper Sandler cuts Inozyme Pharma stock target to $23 - Investing.com
Inozyme Pharma Focuses on ENPP1 Deficiency Program - TipRanks
Inozyme Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating - Marketscreener.com
Inozyme reports prioritization of ENPP1 Deficiency program, workforce reduction - TipRanks
Inozyme Pharma Reports 2024 Financial Results and Strategic Prioritization of ENPP1 Deficiency Program - Nasdaq
Inozyme Pharma, Inc. SEC 10-K Report - TradingView
Form 10-K Inozyme Pharma, Inc. For: Dec 31 - StreetInsider
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization ... - Bluefield Daily Telegraph
Inozyme Pharma Inc Stock (INZY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):